Samsung Bioepis has signed a partnership agreement with the multinational pharmaceutical company Teva Pharmaceuticals to commercialize biosimilars of rare disease treatments in the United States. Samsung Bioepis will launch the biosimilar through Teva in the U.S. market in the first half of this year.

Unlike in Europe, where Samsung Bioepis has been selling its drug directly, the company's strategy in the U.S. has been to forge a partnership to enter the market. Analysts say this is due to the complex structure of the U.S. drug market, which is centered on private insurance, and the cost burden of direct sales.

Samsung Bioepis enters into a partnership with Teva to commercialize Epysqli..